A KFF poll also suggests half of the respondents who had tried these weight loss meds no longer took them, with many reporting difficulties paying for these drugs.
Patients with seropositive RA on stable DMARD therapy showed a CVD risk comparable with that of the general population, unlike those whose treatment regimen was not stable.